Trials / Completed
CompletedNCT02006888
The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 394 (actual)
- Sponsor
- ICON Bioscience Inc · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether IBI-10090 injection is effective in the treatment of inflammation associated with cataract surgery.
Detailed description
A double blinded randomized trial to assess the efficacy and safety of IBI-10090, in two separate doses as compared to placebo (ATEC carrier only sans dexamethasone)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IBI-10090 | |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2014-10-01
- Completion
- 2014-10-01
- First posted
- 2013-12-10
- Last updated
- 2018-04-23
- Results posted
- 2018-04-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02006888. Inclusion in this directory is not an endorsement.